Jump to content

Loteprednol: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Lumentex (talk | contribs)
177 edits
Removed biased statement left uncited for over a year. Removed biased statement cited only with information from the drug manufacturer. DO NOT REVERT WITHOUT PROPER CITATION.
m Added minor internal links - an assumption that an average reader understands some of of the terminology is likely inaccurate.
 
(23 intermediate revisions by 13 users not shown)
Line 1: Line 1:
{{Short description|Pharmaceutical drug}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 5: Line 6:
| IUPAC_name = Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6''H''-cyclopenta[''a'']phenanthrene-17-carboxylate
| IUPAC_name = Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6''H''-cyclopenta[''a'']phenanthrene-17-carboxylate
| image = Loteprednol etabonate.svg
| image = Loteprednol etabonate.svg
| alt =
| drug_name = Loteprednol etabonate
| drug_name =

<!-- Clinical data -->
<!-- Clinical data -->
| tradename = Lotemax
| tradename = Lotemax
Line 11: Line 14:
| MedlinePlus =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
⚫
| routes_of_administration = Eye drops
| pregnancy_category =
| class = [[Corticosteroid]]; [[glucocorticoid]]
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
⚫
| ATC_prefix = S01
⚫
| ATC_suffix = BA14
⚫
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2014 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/resource/guidance/prescription-medicines-registration-new-chemical-entities-australia-2014 | access-date=10 April 2023}}</ref>
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
| legal_US = Rx-only
| legal_status =
| legal_status =

⚫
| routes_of_administration = Eye drops
<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->
| bioavailability = None
| bioavailability = None
Line 26: Line 35:
| elimination_half-life = 2.8 hrs
| elimination_half-life = 2.8 hrs
| excretion =
| excretion =

<!-- Identifiers -->
<!-- Identifiers -->
| IUPHAR_ligand = 7085
| IUPHAR_ligand = 7085
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 82034-46-6
| CAS_number = 82034-46-6
⚫
| ATC_prefix = S01
⚫
| ATC_suffix = BA14
⚫
| ATC_supplemental =
| PubChem = 444025
| PubChem = 444025
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00873
| DrugBank = DB14596
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 392049
| ChemSpiderID = 392049
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = Z8CBU6KR16
| UNII = YEH1EZ96K6
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01689
| KEGG = D01689
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201389
| ChEMBL = 1200865
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 31784
| ChEBI = 31784
| synonyms = 11β,17α,Dihydroxy-21-oxa-21-chloromethylpregna-1,4-diene-3,20-dione 17α-ethylcarbonate
| synonyms = 11β,17α,Dihydroxy-21-oxa-21-chloromethylpregna-1,4-diene-3,20-dione 17α-ethylcarbonate

<!-- Chemical data -->
<!-- Chemical data -->
| C=24 | H=31 | Cl=1 | O=7
| C=24 | H=31 | Cl=1 | O=7
| molecular_weight = 466.951 g/mol
| smiles = CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
| smiles = CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
Line 60: Line 67:
}}
}}


'''Loteprednol''' (as the [[ester]] '''loteprednol etabonate''') is a [[corticosteroid]] used to treat inflammations of the eye. It is marketed by [[Bausch and Lomb]] as '''Lotemax'''<ref name="AC" /> and '''Loterex'''.
'''Loteprednol''' (synthesized as the [[ester]] '''loteprednol etabonate''') is a topical [[corticosteroid]] used to treat inflammations of the eye. It is marketed by [[Bausch and Lomb]] as '''Lotemax'''<ref name="AC" /> and '''Loterex'''.

<!-- Society and culture -->
It was patented in 1980 and approved for medical use in 1998.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR | name-list-style = vanc |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=488 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA488 }}</ref> It is available as a [[generic medication]].<ref>{{cite web | title=First Generic Drug Approvals 2023 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 May 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003621/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023}}</ref>


==Medical uses==
==Medical uses==
Applications for this drug include the reduction of [[inflammation]] after eye surgery,<ref name="AC" /> seasonal [[allergic conjunctivitis]], [[uveitis]],<ref name="Drugs.com" /> as well as chronic forms of [[keratitis]] (e.g. [[adenovirus|adenoviral]] and [[Thygeson's superficial punctate keratopathy|Thygeson's keratitis]]), [[vernal keratoconjunctivitis]], [[Pinguecula|pingueculitis]], and [[episcleritis]].{{citation needed|date=June 2016}}
Applications for this drug include the reduction of [[inflammation]] after eye surgery,<ref name="AC" /> seasonal [[allergic conjunctivitis]], [[uveitis]],<ref name="Drugs.com" /> and chronic forms of [[keratitis]] - such as [[adenovirus|adenoviral]], [[Thygeson's superficial punctate keratopathy|Thygeson's keratitis]], [[vernal keratoconjunctivitis]],[[Pinguecula|pingueculitis]], giant papillary conjunctivitis, and [[episcleritis]].<ref>{{cite journal | vauthors = Pavesio CE, Decory HH | title = Treatment of ocular inflammatory conditions with loteprednol etabonate | journal = The British Journal of Ophthalmology | volume = 92 | issue = 4 | pages = 455–459 | date = April 2008 | pmid = 18245274 | doi = 10.1136/bjo.2007.132621 | s2cid = 25873047 }}</ref>


==Contraindications==
==Contraindications==
As corticosteroids are [[immunosuppressive]], loteprednol is contraindicated in patients with [[virus|viral]], [[fungal]] or [[mycobacterial]] infections of the eye.<ref name="AC" /><ref name="Drugs.com" /><ref name="Dinnendahl" />
[[Contraindication|Contraindications:]] As corticosteroids are [[immunosuppressive]], loteprednol is contraindicated in patients with [[virus|viral]], [[fungal]] or [[mycobacterial]] infections of the eye.<ref name="AC" /><ref name="Drugs.com" /><ref name="Dinnendahl" />


==Adverse effects==
==Adverse effects==
The most common [[Adverse effect|adverse effects]] in patients being treated with the gel formulation are anterior chamber inflammation (in 5% of people), eye pain (2%), and foreign body sensation (2%).<ref name="FDA"/>
Common adverse effects include foreign body sensation in the eye, dry eye and [[epiphora (medicine)|epiphora]] (overflow of tears), [[chemosis]] (swelling of the [[conjunctiva]]), headache, and itching.


==Interactions==
== Interactions ==

The effect of drugs lowering intraocular pressure may be reduced. Loteprednol is not detectable in the bloodstream; so interactions with systemic drugs are highly unlikely.<ref name="AC" />
Because long term use (more than 10 days) can cause increased intraocular pressure, loteprednol may interfere with the treatment of glaucoma. Following ocular administration, the drug is very slowly absorbed into the blood, therefore the blood level is limited to an extremely small concentration, and interactions with drugs taken by mouth or through any route other than topical ophthalmic are very unlikely.<ref name="AC" />


==Pharmacology==
==Pharmacology==


===Mechanism of action===
===Mechanism of action===
{{main article|Glucocorticoid#Mechanism of action}}Corticosteroids mediate their anti-inflammatory effects mainly through the modulation of the cytosolic glucocorticoid receptor (GR) at the genomic level. Preclinical studies demonstrated that loteprednol etabonate is highly lipophilic and has strong binding affinity to glucocorticoid receptors. After it binds to the GR in the cytoplasm, the activated corticosteroid-GR complex migrates to the nucleus, where it upregulates the expression of anti-inflammatory proteins and represses the expression of proinflammatory proteins. Corticosteroids inhibit inflammatory cytokines, chemokines, adhesion molecules, and other inflammatory mediators. They also reduce synthesis of histamine, stabilize cell membranes, and inhibit degranulation of mast cells. Recent work suggests that the activated corticosteroid-GR complex also elicits nongenomic effects, particularly the inhibition of vasodilation, vascular permeability, and migration of leukocytes. <ref>{{cite journal | vauthors = Comstock TL, Decory HH | title = Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate | journal = International Journal of Inflammation | volume = 2012 | pages = 789623 | date = 2012 | pmid = 22536546 | pmc = 3321285 | doi = 10.1155/2012/789623 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Amon M, Busin M | title = Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use | journal = International Ophthalmology | volume = 32 | issue = 5 | pages = 507–517 | date = October 2012 | pmid = 22707339 | pmc = 3459083 | doi = 10.1007/s10792-012-9589-2 }}</ref><ref>{{cite journal | vauthors = Sheppard JD, Comstock TL, Cavet ME | title = Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure | journal = Advances in Therapy | volume = 33 | issue = 4 | pages = 532–552 | date = April 2016 | pmid = 26984315 | pmc = 4846687 | doi = 10.1007/s12325-016-0315-8 }}</ref>
{{main article|Glucocorticoid#Mechanism of action}}


===Pharmacokinetics===
===Pharmacokinetics===
Line 88: Line 99:


<gallery>
<gallery>
File:Cortisol2.svg|[[Cortisol]], a naturally occurring corticosteroid, known as [[hydrocortisone]] when used as a drug
File:Delta1-cortienic acid skeletal.svg|Δ<sup>1</sup>-Cortienic acid, inactive metabolite of loteprednol
File:Delta1-cortienic acid skeletal.svg|Δ<sup>1</sup>-Cortienic acid, inactive metabolite of loteprednol
File:Cortienic acid skeletal.svg|Cortienic acid, inactive metabolite of [[hydrocortisone]]
File:Cortienic acid skeletal.svg|Cortienic acid, inactive metabolite of hydrocortisone
File:Cortisol2.svg|Hydrocortisone, the "parent compound" of corticosteroids
</gallery>
</gallery>


==Chemistry==
==Chemistry==
Loteprednol etabonate is an ester of loteprednol with [[etabonate]] (ethyl carbonate), with a melting point between {{convert|220.5|C|F}} and {{convert|223.5|C|F}}. Its solubility in water is 1:2,000,000.<ref name="Dinnendahl" /> The [[ketone]] in the side chain of classical corticosteroids such as hydrocortisone is replaced by a cleavable ester, which accounts for the rapid inactivation.<ref name="Pavesio" /> (This is not the same as the etabonate ester.)
Loteprednol etabonate is an ester of loteprednol with [[etabonate]] (ethyl carbonate). The pure chemical compound has a melting point between {{convert|220.5|C|F}} and {{convert|223.5|C|F}}. Its solubility in water is 1:2,000,000,<ref name="Dinnendahl" /> therefore it is formulated for ophthalmic use as either an ointment, a gel, or a suspension.<ref name="drugs.com2"/>
Loteprednol is a [[corticosteroid]]. The [[ketone]] side chain of classical corticosteroids such as [[hydrocortisone]] is replaced by a cleavable ester, which accounts for the rapid inactivation.<ref name="Pavesio" /> (This is not the same as the etabonate ester.)
[[Image:Cortisol2.svg|thumb|200px|[[Hydrocortisone]]]]
[[Image:Loteprednol etabonate.svg|thumb|200px|Loteprednol etabonate]]


===Chemical synthesis===
===Chemical synthesis===
Line 101: Line 116:
<ref name="Druzgala" />
<ref name="Druzgala" />


==References==
== References ==
{{reflist|refs=
{{reflist|refs=

⚫
<ref name="AC">{{cite book|title=Austria-Codex|editor=Haberfeld, H.|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref>
<ref name="Drugs.com">Loteprednol {{Drugs.com|ppa|loteprednol}}.</ref>
⚫
<ref name="Druzgala">{{cite journal |author1=Druzgala, P. |author2=Hochhaus, G. |author3=Bodor, N. | title = Soft drugs—10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate | journal = J. Steroid Biochem. Mol. Biol. | date = 1991 | volume = 38 | issue = 2 | pages = 149–54 | doi = 10.1016/0960-0760(91)90120-T| pmid = 2004037 }}</ref>

⚫
<ref name="Dekker">{{cite book|title=Inhaled Steroids in Asthma. Optimizing Effects in the Airways|year=2002|publisher=Marcel Dekker, New York|pages=541–564|author=Bodor, N.|chapter=Design and development of a soft corticosteroid, loteprednol etabonate|author2=Buchwald, P. |editor=Schleimer, R.P. |editor2=O'Byrne, P.M. |editor3=Szefler, S.J. |editor4=Brattsand, R.|work=Lung Biology in Health and Disease, Vol. 163}}</ref>
<ref name="drugs.com2">{{cite web|url=https://www.drugs.com/ppa/loteprednol.html|title=Loteprednol (Professional Patient Advice)|access-date=October 4, 2018}}</ref>
⚫
<ref name="Pavesio">{{cite journal|last=Pavesio|first=C.E.|year=2008|title=Treatment of ocular inflammatory conditions with loteprednol etabonate|journal=Br J Ophthalmol|volume=92|pages=455–459|doi=10.1136/bjo.2007.132621|pmid=18245274|last2=Decory|first2=H.H.|issue=4}}</ref>
<ref name="Dinnendahl">{{cite book|title=Arzneistoff-Profile| vauthors = Dinnendahl V, Fricke U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2008|edition=22|volume=6|isbn=978-3-7741-9846-3|language=German}}</ref>

⚫
<ref name="AC">{{cite book|title=Austria-Codex| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref>

⚫
<ref name="Druzgala">{{cite journal | vauthors = Druzgala P, Hochhaus G, Bodor N | title = Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 38 | issue = 2 | pages = 149–154 | date = February 1991 | pmid = 2004037 | doi = 10.1016/0960-0760(91)90120-T | s2cid = 27107845 }}</ref>

⚫
<ref name="Dekker">{{cite book|title=Inhaled Steroids in Asthma. Optimizing Effects in the Airways|year=2002|publisher=Marcel Dekker, New York|pages=541–564| vauthors = Bodor N, Buchwald P |chapter=Design and development of a soft corticosteroid, loteprednol etabonate | veditors = Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R | series = Lung Biology in Health and Disease | volume = 163 }}</ref>

⚫
<ref name="Pavesio">{{cite journal | vauthors = Pavesio CE, Decory HH | title = Treatment of ocular inflammatory conditions with loteprednol etabonate | journal = The British Journal of Ophthalmology | volume = 92 | issue = 4 | pages = 455–459 | date = April 2008 | pmid = 18245274 | doi = 10.1136/bjo.2007.132621 | s2cid = 25873047 }}</ref>

<ref name="FDA">{{cite web|title= Highlights of Prescribing Information: Lotemax |url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202872lbl.pdf |date=2012}}</ref>

}}
}}


==Further reading==
== Further reading ==
{{refbegin}}
* {{cite journal|last=Steward|first=R.|date=November 1998|title=Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1|journal=J Cataract Refract Surg|volume=24|issue=11|pages=1480–1489|display-authors=etal|pmid=9818338|doi=10.1016/s0886-3350(98)80170-3}}
* {{cite journal | vauthors = Stewart R, Horwitz B, Howes J, Novack GD, Hart K | title = Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1 | journal = Journal of Cataract and Refractive Surgery | volume = 24 | issue = 11 | pages = 1480–1489 | date = November 1998 | pmid = 9818338 | doi = 10.1016/s0886-3350(98)80170-3 | s2cid = 24423725 }}
{{refend}}


{{Glucocorticoids}}
{{Glucocorticoids}}

Latest revision as of 13:54, 23 October 2023

Loteprednol
Clinical data
Trade namesLotemax
Other names11β,17α,Dihydroxy-21-oxa-21-chloromethylpregna-1,4-diene-3,20-dione 17α-ethylcarbonate
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Eye drops
Drug classCorticosteroid; glucocorticoid
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNone
Protein binding95%
MetabolismEster hydrolysis
MetabolitesΔ1-cortienic acid and its etabonate
Onset of action≤2 hrs (allergic conjunctivitis)
Elimination half-life2.8 hrs
Identifiers
  • Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.167.120 Edit this at Wikidata
Chemical and physical data
FormulaC24H31ClO7
Molar mass466.96 g·mol−1
3D model (JSmol)
Melting point220.5 to 223.5 °C (428.9 to 434.3 °F)
Solubility in water0.0005 mg/mL (20 °C)
  • CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
  • InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1 ☒N
  • Key:DMKSVUSAATWOCU-HROMYWEYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Loteprednol (synthesized as the ester loteprednol etabonate) is a topical corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax[2] and Loterex.

It was patented in 1980 and approved for medical use in 1998.[3] It is available as a generic medication.[4]

Medical uses

[edit]

Applications for this drug include the reduction of inflammation after eye surgery,[2] seasonal allergic conjunctivitis, uveitis,[5] and chronic forms of keratitis - such as adenoviral, Thygeson's keratitis, vernal keratoconjunctivitis,pingueculitis, giant papillary conjunctivitis, and episcleritis.[6]

Contraindications

[edit]

Contraindications: As corticosteroids are immunosuppressive, loteprednol is contraindicated in patients with viral, fungal or mycobacterial infections of the eye.[2][5][7]

Adverse effects

[edit]

The most common adverse effects in patients being treated with the gel formulation are anterior chamber inflammation (in 5% of people), eye pain (2%), and foreign body sensation (2%).[8]

Interactions

[edit]

Because long term use (more than 10 days) can cause increased intraocular pressure, loteprednol may interfere with the treatment of glaucoma. Following ocular administration, the drug is very slowly absorbed into the blood, therefore the blood level is limited to an extremely small concentration, and interactions with drugs taken by mouth or through any route other than topical ophthalmic are very unlikely.[2]

Pharmacology

[edit]

Mechanism of action

[edit]
Main article: Glucocorticoid § Mechanism of action

Corticosteroids mediate their anti-inflammatory effects mainly through the modulation of the cytosolic glucocorticoid receptor (GR) at the genomic level. Preclinical studies demonstrated that loteprednol etabonate is highly lipophilic and has strong binding affinity to glucocorticoid receptors. After it binds to the GR in the cytoplasm, the activated corticosteroid-GR complex migrates to the nucleus, where it upregulates the expression of anti-inflammatory proteins and represses the expression of proinflammatory proteins. Corticosteroids inhibit inflammatory cytokines, chemokines, adhesion molecules, and other inflammatory mediators. They also reduce synthesis of histamine, stabilize cell membranes, and inhibit degranulation of mast cells. Recent work suggests that the activated corticosteroid-GR complex also elicits nongenomic effects, particularly the inhibition of vasodilation, vascular permeability, and migration of leukocytes. [9][10][11]

Pharmacokinetics

[edit]

Neither loteprednol etabonate nor its inactive metabolites Δ1-cortienic acid and Δ1-cortienic acid etabonate are detectable in the bloodstream, even after oral administration. A study with patients receiving loteprednol eye drops over 42 days showed no adrenal suppression, which would be a sign of the drug reaching the bloodstream to a clinically relevant extent.[2]

Steroid receptor affinity was 4.3 times that of dexamethasone in animal studies.[2]

Retrometabolic drug design

[edit]

Loteprednol etabonate was developed using retrometabolic drug design. It is a so-called soft drug, meaning its structure was designed so that it is predictably metabolised to inactive substances. These metabolites, Δ1-cortienic acid and its etabonate, are derivatives of cortienic acid, itself an inactive metabolite of hydrocortisone.[2][7][12]

  • Cortisol, a naturally occurring corticosteroid, known as hydrocortisone when used as a drug
    Cortisol, a naturally occurring corticosteroid, known as hydrocortisone when used as a drug
  • Δ1-Cortienic acid, inactive metabolite of loteprednol
    Δ1-Cortienic acid, inactive metabolite of loteprednol
  • Cortienic acid, inactive metabolite of hydrocortisone
    Cortienic acid, inactive metabolite of hydrocortisone

Chemistry

[edit]

Loteprednol etabonate is an ester of loteprednol with etabonate (ethyl carbonate). The pure chemical compound has a melting point between 220.5 °C (428.9 °F) and 223.5 °C (434.3 °F). Its solubility in water is 1:2,000,000,[7] therefore it is formulated for ophthalmic use as either an ointment, a gel, or a suspension.[13]

Loteprednol is a corticosteroid. The ketone side chain of classical corticosteroids such as hydrocortisone is replaced by a cleavable ester, which accounts for the rapid inactivation.[14] (This is not the same as the etabonate ester.)

Hydrocortisone
Loteprednol etabonate

Chemical synthesis

[edit]

[15]

References

[edit]
  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ a b c d e f g Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
  4. ^ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  5. ^ a b Loteprednol Professional Drug Facts.
  6. ^ Pavesio CE, Decory HH (April 2008). "Treatment of ocular inflammatory conditions with loteprednol etabonate". The British Journal of Ophthalmology. 92 (4): 455–459. doi:10.1136/bjo.2007.132621. PMID 18245274. S2CID 25873047.
  7. ^ a b c Dinnendahl V, Fricke U (2008). Arzneistoff-Profile (in German). Vol. 6 (22 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
  8. ^ "Highlights of Prescribing Information: Lotemax" (PDF). 2012.
  9. ^ Comstock TL, Decory HH (2012). "Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate". International Journal of Inflammation. 2012: 789623. doi:10.1155/2012/789623. PMC 3321285. PMID 22536546.
  10. ^ Amon M, Busin M (October 2012). "Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use". International Ophthalmology. 32 (5): 507–517. doi:10.1007/s10792-012-9589-2. PMC 3459083. PMID 22707339.
  11. ^ Sheppard JD, Comstock TL, Cavet ME (April 2016). "Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure". Advances in Therapy. 33 (4): 532–552. doi:10.1007/s12325-016-0315-8. PMC 4846687. PMID 26984315.
  12. ^ Bodor N, Buchwald P (2002). "Design and development of a soft corticosteroid, loteprednol etabonate". In Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R (eds.). Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Lung Biology in Health and Disease. Vol. 163. Marcel Dekker, New York. pp. 541–564.
  13. ^ "Loteprednol (Professional Patient Advice)". Retrieved October 4, 2018.
  14. ^ Pavesio CE, Decory HH (April 2008). "Treatment of ocular inflammatory conditions with loteprednol etabonate". The British Journal of Ophthalmology. 92 (4): 455–459. doi:10.1136/bjo.2007.132621. PMID 18245274. S2CID 25873047.
  15. ^ Druzgala P, Hochhaus G, Bodor N (February 1991). "Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate". The Journal of Steroid Biochemistry and Molecular Biology. 38 (2): 149–154. doi:10.1016/0960-0760(91)90120-T. PMID 2004037. S2CID 27107845.

Further reading

[edit]
  • Stewart R, Horwitz B, Howes J, Novack GD, Hart K (November 1998). "Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1". Journal of Cataract and Refractive Surgery. 24 (11): 1480–1489. doi:10.1016/s0886-3350(98)80170-3. PMID 9818338. S2CID 24423725.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Loteprednol&oldid=1181510638"